Keywords
Hanseniasis
Therapy
Dapsone
Genetics
Pharmacogenetins
Therapy
Dapsone
Genetics
Pharmacogenetins
How to Cite
1.
BEIGUELMAN B. Leprosy therapy and pharmacogenetics. Hansen. Int. [Internet]. 1976 Jun. 30 [cited 2024 Nov. 21];1(1):61-78. Available from: https://periodicos.saude.sp.gov.br/hansenologia/article/view/35676
Abstract
Some pharmacogenetic traits which are human genetic polymorphisms and that influence the action of 4, V-piaminodiphenylsulfone (DDS), the most widely used drug in leprosy therapy, were analysed. Special attention was given to the polymorphisms of acetyltransferase, glucose-6-phosphate dehydrogenase and NADH methemoglobin reductase. Besides the review and critical analysis of the pertinent literature, suggestions for further investigations are presented.
References
1. ALEXANDER, J. O. Dapsone in the treatment of dermatitis herpetiformis. Lancet, 268(6876) :1201-1202, 1955.
2. ALLDAY, E. J. & BARNES, J. Toxic effects of diaminodiphenylsulphone in the treatment of leprosy. Lancet, 261(6675) :205-206, 1951.
3. ALLISON, A. C. & REES, W. The binding of haemoglobin by plasma proteins (haptoglobins). Its bearing on the "renal threshold" for haemoglobin and the aethiology of haemoglobinuria. Br. Med. J., (5054) :1137-1143, 1957.
4. BECHELLI, L. M. Leprosy today. World Health: 10-19, Oct. 1971.
5. BECHELLI, L. M. & MARTINEZ-DOMINGUEZ, V. The Leprosy problem in the world. Bull. World Health Organ., 34:811-826, 1966.
6. BEIGUELMAN, B. Reação gustativa b. fenil-tio-carbamida (PTC) e lepra. Rev. Bras. Leprol., 30:111-124, 1962.
7. BEIGUELMAN, B. Taste sensitivity to phenylthiourea among patients affected with both tuberculosis and leprosy. Acta Genet. Med. Gemellol., 13(2): 190-192, 1964.
8. BEIGUELMAN, B. Taste sensitivity to phenylthiourea and leprosy. Acta Genet. Med. Gemellol., 13(2) :193-196, 1964.
9. BEIGUELMAN, B. & MARQUES, M. B. Taste sensitivity to phenylthiourea and drugs with antileprotic effect. Acta Genet. Med. Gemellol., 13(2): 200-202, 1964.
10. BEIGUELMAN, B.; PINTO JR., W.; DALL'AGLIO, F. F.; SILVA, E.; VOZZA, J. A. Deficiência da desidrogenase de 6-fosfato de glicose (G-6PD) e lepra. In: REUNIÃO ANUAL DA SBPC, 18.°, Blumenau, SC, 1966. Resumo das comunicagdes.[s.n.t.] apud Ciência e Cultura, 18(2) :95-96, 1966.
11. BEIGUELMAN, B.; PINTO JR., W.; DALL'AGLIO, F. F.; SILVA, E.; VOZZA, J. A. G-6PD deficiency among lepers and healthy people in
Brazil. Acta Genet., (Basel), 18:159-162, 1968.
12. BEIGUELMAN, B.; PINTO JR., W.; EL-GUINDY, M. M.; KRIEGER, H. Factors influencing the level of DDS in blood. Bull. World Health Organ., 51:467-471, 1974.
13. BELDA, W. Resultados preliminares no tratamento da reação hansênica com o dextrosulfenidol. Rev. Bras. Leprol., 37(1/4) :5-16, 1970.
14. BRUCE-CHWATT, L. J. Changing tides of chemotherapy of malaria. Brit. Med. J., 1(5383) :581-586, 1964.
15. COCHRANE, R. G. Critical review of present position of sulfone therapy in leprosy. Trans. Roy. Soc. Trop. Med. Hyg., 44:259-270, 1950.
16. COHEN, R. J.; SACHS, J. R.; WICKER, D. J.; CONRAD, M. E. Methemo- globinemia provoked by malarial chemoprophylaxis in Vietnam. New Engl. J. Med., 279(21) :1127-1131, 1968.
17. CONVIT, J.; BROWNE, S. G.; LANGUILLON, J.• PETTIT, J. H. S.• RAMA- NUJAM, K.; SAGHER, F.; SHESKIN, J.-' SOUZA-LIMA, L.•' TARABINI, G.; TOLENTINO, J. G.; WATERS, IW. F. R.; BECHELLI, L. M.; MAR- TINEZ-DOMINGUEZ, V. Therapy of leprosy. Bull. World Health Or- gan., 42(5) :667-672, 1970.
18. DeGOWIN, R. L. A review of therapeutic and hemolytic effects of dapsone. Arch. Intern. Med., 120:242-248, 1967.
19. DeGOWIN, R. L.; EPPES, R. B.; POWELL, R. D.; CARSON, P. E. The haemolytic effects of diaphenylsulfone (DDS) in normal subjects and in those with glucose-6-phosphate-dehydrogenase deficiency. Bull. World Health Organ., 35(2) :165-179, 1967.
20. DESFORGES, J. F.; THAYER, W. W.•' DAWSON, J. P. Hemolytic anemia induced by sulfoxone therapy, with investigation into the mechanisms of its production. Am. J. Med., 27:132-136, 1959.
21. ELLARD, G. A.; GAMMON, P. T.; HELMY, H. S.; REES, R. J. W. Dapsone acetylation and the treatment of leprosy. Nature, 239:159-160, 1972.
22. EVANS, D. A. P.• MANLEY, K. A.; McKUSICK, V. A. Genetic control of isoniazid metabolism in man. Br. Med. J., 1 (5197) :485-491, 1960.
23. EVANS, D. A. P. & WHITE, T. A. Human acetvlation polymorphism. J. Lab. Clin. Med., 68:394-403, 1964.
24. FABRO, S.; SHUMACHER, H.; SMITH, R. L.; STAGG, R. B. L.; WILLIAMS, R. T. The metabolism of thalidomide: some biological effects of thalido- mide and its metabolites. Br. J. Pharmacol., 25:352-362, 1965.
25. GELBER, R.; PETERS, J. H.; GORDON, G. R.; GLAZKO, A. J.; LEVY, L. The polymorphic acetylation of dapsone in man. Clin. Pharmacol. The- rapeut., 12:225-238, 1971.
26. GILLES, H. 1W. & TAYLOR, B. G. The existence of the glucose-6-phosphate dehydrogenase deficiency trait in Nigeria and its clinical implications. Ann. Trop. Med. Parasitol., 55:64-69, 1961.
27. HARRIS, H. & KALMUS, H. Chemical specificity in genetical differences of taste sensitivity. Ann. Eugen., 15:32-45, 1949.
28. HJELM, M. & VERDIER, C. H. D. Biochemical effects of aromatic amines. I. Methaemoglobinaemia, heamolysis and Heinz-body formation induced by 4,4'- diaminodiphenylsulphone. Biochem. Pharmacol., /4:1119-1128, 1965.
29. HOPKINS, C. Y. A sulphur containing substance from the seed of Coringia Orientalis. Canad. J. Res. B., 16:341-344, 1938.
30. HOPKINS, C. Y. Taste differences in compounds having NCS linkage. Canad. J. Res. B., 20:268-273 ,1942.
31. IYER, C. G. S.; LANGUILLON, J.; RAMANUJAM, K.; TARABINI-CAS- TELLANI, G.; TERENCIO DE LAS AGUAS, J.; BECHELLI, L. M.; UEMURA, K.; MARTINEZ DOMINGUEZ, V.; SUNUARESAN, T. Who co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull. World Health Organ., 45:719-732, 1971.
32. JELLIFFE, D. B. Toxic hepatitis caused by diaminocliphenyl-sulphone. Lancet, 260(6670) :1343-1344, 1951.
33. KNIGHT, R. A.; SELIN, M. J.; HARRIS, H. W. Genetic factors influencing isoniazid blood levels in humans. In: CONFERENCE ON CHEMOTHE- RAPY OF TUBERCULOSIS, 18th, Washington, D.C., 1959. Transactions. p.52.
34. LANGUILLON, J. & LINHARD, J. Research on association between genetic factors and leprosy in Africa. In: INTERNATIONAL LEPROSY CON- GRESS, 10th, Bergen, 1973. Transactions apud Int. J. Leprosy, 41(4): 603, 1973.
35. LECHAT, M. F.; BIAS, W. B.; BLUMBERG, B. S.; MELARTIN, L.; QUINTO, R. S.; COHEN, B. H.; TOLENTINO, J. G.; ABALOS, R. M. A con- trolled study of polyraorphisms in serum globulin and glucose-6-phosphate dehydrogenase deficiency in leprosy. Int. J. Leprosy, 36(2) :179-191, 1968.
36. LEIKER, D. L. The mononucleosis syndrome in leprosy patients treated with sulfones. Int. J. Leprosy, 24(4) :402-405, 1966.
37. LEIKER, D. L. & KAMP, H. First results of treatment of leprosy with rifadin. Lepr. Rev., 41(1) :25-30, 1970.
38. LEWGOY, F. & SALZANO, F. M. Dinâmica do gen que condiciona a de- ficiência em G-6-PD na população de Porto Alegre. In: REUNIÃO ANUAL DA SBPC, 17ª, Belo Horizonte, M.G., 1966. Resumo das comunicações. [s.n.t.] apud Ciência e Cultura, 17(2): 152, 1965.
39. LINCOLN, E. M.; STONE, S.; HOFFMAN, O. R. The treatment of miliary tuberculosis with promizole. Bull. Johns Hopkins Hosp., 82:56-75, 1948.
40. LINN, H. W. The use of dapsone in dermatology. Aust. J. Derm., 6:203-207, 1962.
41. LORINCZ, A. L. & PEARSON, R. W. Sulfapyridine and sulfone type drugs in dermatology. Arch. Dermatol., 85(1) :2-16, 1962.
42. MARQUES, M. B. & OPROMOLLA, D. V. A. A talidomida no tratamento da reação leprótica. Rev. Bras. Leprol., 37(1/4) :41-49, 1970.
43. McRAE, D. H.; RUSSEL, D. A.; SCOTT, G. C.; VINCIN, D. R.; SHEPARD, C. C. Four year results in the therapeutic trial of acedapsone (DADDS) in the Karimui, New Guinea. Int. J. Leprosy, 40(2) :222-223, 1972.
44. MENON, N. K. Madras study of two once-weekly regimens. Clinical aspects. Proc. Int. Tuberc. Conf., (New York, 1969). Bull. Int. Union Against Tuberc., 43:271-275, 1970.
45. MIGUEZ ALONSO, A. Tratamento especifico. In: BRASIL. Ministério da Saúde. Serviço Nacional de Lepra. Manual de Leprologia. Rio de Ja- neiro, 1960. p.97-118.
46. MOLESWORTH, B. D.; NARAYANASWAMI, P. S.; SIMPSON, I. A. The treatment of lepromatous leprosy with 4:4'-diaminodiphenyl sulfone in oil: findings in 100 cases treated for one year' with a note on the technique of sulfone determinations. Int. J. Leprosy. 17(3) :197-210, 1949.
47. MOTULSKY, A. G. Pharmacogenetics. Progr. Med. Genet., 3:49-74, 1964.
48. ORGANISATION MONDIALE DE LA SANTA. Série de Rapports Techniques. Resistance des parasites du paludisme aux medicaments. Rapport d'un Groupe scientifique de l'OMS. Genève, n.° 296, 1965.
49. ORGANIZACIÓN MUNDIAL DE LA SALUD. Serie de Informes Técnicos. Farmacogenetica. Informe de un Grupo Cientifico de la OMS. Genebra, n.° 524, 1973.
50. OPROMOLLA, D. V. A. First results of the use of rifamycin SV in the treatment of lepromatous leprosy. hit. J. Leprosy, 31 :552, 1963.
51. OPROMOLLA, D. V. A. & ALMEIDA, S. C. Primeiros resultados do trata- mento da lepra com kanamicina. Rev. Bras. Leprol., 37(1/4) :17-39, 1970.
52. OPROMOLLA, D. V. A.; PESSOA-MENDES, J.; SOUZA-LIMA, L. A terra- micina na lepra. Rev. Bras. Leprol., 38(1/4) :1-21, 1965.
53. OPROMOLLA, D. V. A.; SOUZA-LIMA, L.; CAPRARA, G. Rifamycin SV in the treatment of lepromatous leprosy. Lepr. Rev., 86(3) :123-131, 1966.
54. OWEN, J. A.; MACKAY, I. R.; GOT, C. Serum haptoglobins in hepatobiliary disease. Br. Med. J., (5135) :1454-1457, 1959.
55. PETERS, J. H.; GORDON, G. R.; BROWN, P. The relationship between the capacities of human subjects to acetylate isoniazid, sulfanilamide and sulfamethazine. Life Sol., 4:99-107, 1965.
56. PETERS, J. H.; GORDON, G. R.; GHOUL, D. C.; TOLENTINO, J. G.; WALSH, G. P.; LEVY,L. The disposition of the antileprotic drug dapsone (DDS) in Philippine subjets. Am. J. Trop. Med. Hyg., 21:450-457, 1972.
57. PETERS, J. H.; GORDON, G. R.; KARAT, A. B. A.; MEYERS, W. M. Metabolic disposition of dapsone in Indian and African subjects. In: ANNUAL LEPROSY RESEARCH CONFERENCE, 7th, California, 1972 apud Int. J. Leprosy, 40(2) :221-222, 1972.
58. PETERS, J. H.; GORDON, G. R.; LEVY, L.; STORKAN, M. A.; JACOBSON, R. R.; ENNA, C. D.; KIRCHHEIMER, W. F. Metabolic disposition of dapsone in patients with dapsone-resistant leprosy. Am. J. Trop. Med. Hyg., 23:222-230, 1972.
59. PETTIT, J. H. S. & CHIN, J. Does glucose-6-phosphate dehydrogenase defi- ciency modify the course of leprosy or its treatment. Lepr. Rev., 35(4): 149-156, 1964.
60. POVEY, M. S. & HORTON, R. J. Leprosy and blood groups. Lepr. Rev. 37:147-150, 1966.
61. RAMOS E SILVA, J. Sur le traitement de la 16pre, en particulier de l'hypodermite nodulaire lepromateuse recidivante par la griseofulvine. Dermat. Internat., 7:37-42, 1968 apud /nt. J. Leprosy, 37:208, 1969.
62. BEES, R. J. W. Rifampicin as therapy in lepromatous leprosy. Star, 33 (4): 5, 12, 1974.
63. REES, R. J. W.; PEARSON, J. M. H.; WATERS, M. F. R. Experimental and clinical studies on rifampicin in the treatment of leprosy. Br. Med. J., 1:89-92, 1970.
64. SCHWANTES, A. R.; SALZANO, F. M.; CASTRO, I. V.; TONDO, C. V. Haptoglobins and leprosy. Acta Genet. (Basel), 17:127-136, 1967.
65. SHEPARD, C. C. The first decade in experimental leprosy. Bull. World Health Organ., 44(6) :821-827, 1971.
66. SHESKIN, J. Further observation with thalidomide in lepra reactions. Lepr. Rev., 36:183-187, 1965.
67. SLOAN, N. R.; JANO, B.; WORTH, R. M.; FASAL, P.•' SHEPARD, C. C. Repository acedapsone in leprosy chemoprophylaxis and treatment. Lancet, 2:525-526, 1971.
68. SOUZA-LIMA, L. Considerageies sobre o real valor da sulfonoterapia nos pro- gramas de profilaxia da lepra. Rev. Bras. Leprol., 86(1/4) :31-36, 1968/ 1969.
69. SUNAHARA, S.; URANO, M.; LIN, H. T.; CHEG, T. J.•' JARUMILINDA, A. Further observations on trimodality of frequency distribution curve of bio- logically ative isoniazid blood levels and 'cline' in frequencies of alleles controlling isoniazid inactivation. Acta Tuberc. Pneumol. Scand., 43 :181- 195, 1963.
70. SUNAHARA, S.; URANO, M.; OGAWA, M. Genetical and geographic studies on isoniazid inactivation. Science, 134:1530-1531, 1961.
71. TAUSSIG, H. B. A study of the German outbreak of phocomelia. The tha- lidomide syndrome. J. Amer. med. Ass., /80:1106-1113, 1962.
72. TUBERCULOSIS CHEMOTHERAPY CENTRE, Madras. A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis. Bull. World Health Organ., 48(1): 143-206, 1970.73. VESELL, E. S. Recent progress in pharmacogenetics. Adv. Pharmacol. Chemother., 7:1-52, 1969.
74. WEINSTEIN, L. Medicamentos utilizados na quimioterapia da lepra e da tuberculose. In: GOODMAN, L. S. & GILMAN, A., ed. As bases farmacológicas da terapêutica. [trad. de Lauro SoHero] 4.a ed. Rio de Janeiro, Guanabara Koogan, 1973. cap. 61, p. 1211-1241.
75. WOLF, M. Dermatitis herpetiformis: response to diaminodiphenylsulfone. Arch. Derm,atol., 82(6) :1020-1021, 1960.
76. WORLD HEALTH ORGANIZATION. Technical Report Series. WHO expert committee on leprosy. Fourth report. Geneva, n.° 459, 1970.
77. YOSHIDA, A. Hemolytic anemia and G6PD deficiency. Science, 179 :532- 537, 1973.
78. ZINKHAM, W. H.; LENHARD JR., R. E.; CHILDS, B. Deficiency of glucose 6-phosphate dehydrogenase activity in erythrocytes from patients with favism. Bull. Johns Hopkins Hosp., 102:169-175, 1958.
2. ALLDAY, E. J. & BARNES, J. Toxic effects of diaminodiphenylsulphone in the treatment of leprosy. Lancet, 261(6675) :205-206, 1951.
3. ALLISON, A. C. & REES, W. The binding of haemoglobin by plasma proteins (haptoglobins). Its bearing on the "renal threshold" for haemoglobin and the aethiology of haemoglobinuria. Br. Med. J., (5054) :1137-1143, 1957.
4. BECHELLI, L. M. Leprosy today. World Health: 10-19, Oct. 1971.
5. BECHELLI, L. M. & MARTINEZ-DOMINGUEZ, V. The Leprosy problem in the world. Bull. World Health Organ., 34:811-826, 1966.
6. BEIGUELMAN, B. Reação gustativa b. fenil-tio-carbamida (PTC) e lepra. Rev. Bras. Leprol., 30:111-124, 1962.
7. BEIGUELMAN, B. Taste sensitivity to phenylthiourea among patients affected with both tuberculosis and leprosy. Acta Genet. Med. Gemellol., 13(2): 190-192, 1964.
8. BEIGUELMAN, B. Taste sensitivity to phenylthiourea and leprosy. Acta Genet. Med. Gemellol., 13(2) :193-196, 1964.
9. BEIGUELMAN, B. & MARQUES, M. B. Taste sensitivity to phenylthiourea and drugs with antileprotic effect. Acta Genet. Med. Gemellol., 13(2): 200-202, 1964.
10. BEIGUELMAN, B.; PINTO JR., W.; DALL'AGLIO, F. F.; SILVA, E.; VOZZA, J. A. Deficiência da desidrogenase de 6-fosfato de glicose (G-6PD) e lepra. In: REUNIÃO ANUAL DA SBPC, 18.°, Blumenau, SC, 1966. Resumo das comunicagdes.[s.n.t.] apud Ciência e Cultura, 18(2) :95-96, 1966.
11. BEIGUELMAN, B.; PINTO JR., W.; DALL'AGLIO, F. F.; SILVA, E.; VOZZA, J. A. G-6PD deficiency among lepers and healthy people in
Brazil. Acta Genet., (Basel), 18:159-162, 1968.
12. BEIGUELMAN, B.; PINTO JR., W.; EL-GUINDY, M. M.; KRIEGER, H. Factors influencing the level of DDS in blood. Bull. World Health Organ., 51:467-471, 1974.
13. BELDA, W. Resultados preliminares no tratamento da reação hansênica com o dextrosulfenidol. Rev. Bras. Leprol., 37(1/4) :5-16, 1970.
14. BRUCE-CHWATT, L. J. Changing tides of chemotherapy of malaria. Brit. Med. J., 1(5383) :581-586, 1964.
15. COCHRANE, R. G. Critical review of present position of sulfone therapy in leprosy. Trans. Roy. Soc. Trop. Med. Hyg., 44:259-270, 1950.
16. COHEN, R. J.; SACHS, J. R.; WICKER, D. J.; CONRAD, M. E. Methemo- globinemia provoked by malarial chemoprophylaxis in Vietnam. New Engl. J. Med., 279(21) :1127-1131, 1968.
17. CONVIT, J.; BROWNE, S. G.; LANGUILLON, J.• PETTIT, J. H. S.• RAMA- NUJAM, K.; SAGHER, F.; SHESKIN, J.-' SOUZA-LIMA, L.•' TARABINI, G.; TOLENTINO, J. G.; WATERS, IW. F. R.; BECHELLI, L. M.; MAR- TINEZ-DOMINGUEZ, V. Therapy of leprosy. Bull. World Health Or- gan., 42(5) :667-672, 1970.
18. DeGOWIN, R. L. A review of therapeutic and hemolytic effects of dapsone. Arch. Intern. Med., 120:242-248, 1967.
19. DeGOWIN, R. L.; EPPES, R. B.; POWELL, R. D.; CARSON, P. E. The haemolytic effects of diaphenylsulfone (DDS) in normal subjects and in those with glucose-6-phosphate-dehydrogenase deficiency. Bull. World Health Organ., 35(2) :165-179, 1967.
20. DESFORGES, J. F.; THAYER, W. W.•' DAWSON, J. P. Hemolytic anemia induced by sulfoxone therapy, with investigation into the mechanisms of its production. Am. J. Med., 27:132-136, 1959.
21. ELLARD, G. A.; GAMMON, P. T.; HELMY, H. S.; REES, R. J. W. Dapsone acetylation and the treatment of leprosy. Nature, 239:159-160, 1972.
22. EVANS, D. A. P.• MANLEY, K. A.; McKUSICK, V. A. Genetic control of isoniazid metabolism in man. Br. Med. J., 1 (5197) :485-491, 1960.
23. EVANS, D. A. P. & WHITE, T. A. Human acetvlation polymorphism. J. Lab. Clin. Med., 68:394-403, 1964.
24. FABRO, S.; SHUMACHER, H.; SMITH, R. L.; STAGG, R. B. L.; WILLIAMS, R. T. The metabolism of thalidomide: some biological effects of thalido- mide and its metabolites. Br. J. Pharmacol., 25:352-362, 1965.
25. GELBER, R.; PETERS, J. H.; GORDON, G. R.; GLAZKO, A. J.; LEVY, L. The polymorphic acetylation of dapsone in man. Clin. Pharmacol. The- rapeut., 12:225-238, 1971.
26. GILLES, H. 1W. & TAYLOR, B. G. The existence of the glucose-6-phosphate dehydrogenase deficiency trait in Nigeria and its clinical implications. Ann. Trop. Med. Parasitol., 55:64-69, 1961.
27. HARRIS, H. & KALMUS, H. Chemical specificity in genetical differences of taste sensitivity. Ann. Eugen., 15:32-45, 1949.
28. HJELM, M. & VERDIER, C. H. D. Biochemical effects of aromatic amines. I. Methaemoglobinaemia, heamolysis and Heinz-body formation induced by 4,4'- diaminodiphenylsulphone. Biochem. Pharmacol., /4:1119-1128, 1965.
29. HOPKINS, C. Y. A sulphur containing substance from the seed of Coringia Orientalis. Canad. J. Res. B., 16:341-344, 1938.
30. HOPKINS, C. Y. Taste differences in compounds having NCS linkage. Canad. J. Res. B., 20:268-273 ,1942.
31. IYER, C. G. S.; LANGUILLON, J.; RAMANUJAM, K.; TARABINI-CAS- TELLANI, G.; TERENCIO DE LAS AGUAS, J.; BECHELLI, L. M.; UEMURA, K.; MARTINEZ DOMINGUEZ, V.; SUNUARESAN, T. Who co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull. World Health Organ., 45:719-732, 1971.
32. JELLIFFE, D. B. Toxic hepatitis caused by diaminocliphenyl-sulphone. Lancet, 260(6670) :1343-1344, 1951.
33. KNIGHT, R. A.; SELIN, M. J.; HARRIS, H. W. Genetic factors influencing isoniazid blood levels in humans. In: CONFERENCE ON CHEMOTHE- RAPY OF TUBERCULOSIS, 18th, Washington, D.C., 1959. Transactions. p.52.
34. LANGUILLON, J. & LINHARD, J. Research on association between genetic factors and leprosy in Africa. In: INTERNATIONAL LEPROSY CON- GRESS, 10th, Bergen, 1973. Transactions apud Int. J. Leprosy, 41(4): 603, 1973.
35. LECHAT, M. F.; BIAS, W. B.; BLUMBERG, B. S.; MELARTIN, L.; QUINTO, R. S.; COHEN, B. H.; TOLENTINO, J. G.; ABALOS, R. M. A con- trolled study of polyraorphisms in serum globulin and glucose-6-phosphate dehydrogenase deficiency in leprosy. Int. J. Leprosy, 36(2) :179-191, 1968.
36. LEIKER, D. L. The mononucleosis syndrome in leprosy patients treated with sulfones. Int. J. Leprosy, 24(4) :402-405, 1966.
37. LEIKER, D. L. & KAMP, H. First results of treatment of leprosy with rifadin. Lepr. Rev., 41(1) :25-30, 1970.
38. LEWGOY, F. & SALZANO, F. M. Dinâmica do gen que condiciona a de- ficiência em G-6-PD na população de Porto Alegre. In: REUNIÃO ANUAL DA SBPC, 17ª, Belo Horizonte, M.G., 1966. Resumo das comunicações. [s.n.t.] apud Ciência e Cultura, 17(2): 152, 1965.
39. LINCOLN, E. M.; STONE, S.; HOFFMAN, O. R. The treatment of miliary tuberculosis with promizole. Bull. Johns Hopkins Hosp., 82:56-75, 1948.
40. LINN, H. W. The use of dapsone in dermatology. Aust. J. Derm., 6:203-207, 1962.
41. LORINCZ, A. L. & PEARSON, R. W. Sulfapyridine and sulfone type drugs in dermatology. Arch. Dermatol., 85(1) :2-16, 1962.
42. MARQUES, M. B. & OPROMOLLA, D. V. A. A talidomida no tratamento da reação leprótica. Rev. Bras. Leprol., 37(1/4) :41-49, 1970.
43. McRAE, D. H.; RUSSEL, D. A.; SCOTT, G. C.; VINCIN, D. R.; SHEPARD, C. C. Four year results in the therapeutic trial of acedapsone (DADDS) in the Karimui, New Guinea. Int. J. Leprosy, 40(2) :222-223, 1972.
44. MENON, N. K. Madras study of two once-weekly regimens. Clinical aspects. Proc. Int. Tuberc. Conf., (New York, 1969). Bull. Int. Union Against Tuberc., 43:271-275, 1970.
45. MIGUEZ ALONSO, A. Tratamento especifico. In: BRASIL. Ministério da Saúde. Serviço Nacional de Lepra. Manual de Leprologia. Rio de Ja- neiro, 1960. p.97-118.
46. MOLESWORTH, B. D.; NARAYANASWAMI, P. S.; SIMPSON, I. A. The treatment of lepromatous leprosy with 4:4'-diaminodiphenyl sulfone in oil: findings in 100 cases treated for one year' with a note on the technique of sulfone determinations. Int. J. Leprosy. 17(3) :197-210, 1949.
47. MOTULSKY, A. G. Pharmacogenetics. Progr. Med. Genet., 3:49-74, 1964.
48. ORGANISATION MONDIALE DE LA SANTA. Série de Rapports Techniques. Resistance des parasites du paludisme aux medicaments. Rapport d'un Groupe scientifique de l'OMS. Genève, n.° 296, 1965.
49. ORGANIZACIÓN MUNDIAL DE LA SALUD. Serie de Informes Técnicos. Farmacogenetica. Informe de un Grupo Cientifico de la OMS. Genebra, n.° 524, 1973.
50. OPROMOLLA, D. V. A. First results of the use of rifamycin SV in the treatment of lepromatous leprosy. hit. J. Leprosy, 31 :552, 1963.
51. OPROMOLLA, D. V. A. & ALMEIDA, S. C. Primeiros resultados do trata- mento da lepra com kanamicina. Rev. Bras. Leprol., 37(1/4) :17-39, 1970.
52. OPROMOLLA, D. V. A.; PESSOA-MENDES, J.; SOUZA-LIMA, L. A terra- micina na lepra. Rev. Bras. Leprol., 38(1/4) :1-21, 1965.
53. OPROMOLLA, D. V. A.; SOUZA-LIMA, L.; CAPRARA, G. Rifamycin SV in the treatment of lepromatous leprosy. Lepr. Rev., 86(3) :123-131, 1966.
54. OWEN, J. A.; MACKAY, I. R.; GOT, C. Serum haptoglobins in hepatobiliary disease. Br. Med. J., (5135) :1454-1457, 1959.
55. PETERS, J. H.; GORDON, G. R.; BROWN, P. The relationship between the capacities of human subjects to acetylate isoniazid, sulfanilamide and sulfamethazine. Life Sol., 4:99-107, 1965.
56. PETERS, J. H.; GORDON, G. R.; GHOUL, D. C.; TOLENTINO, J. G.; WALSH, G. P.; LEVY,L. The disposition of the antileprotic drug dapsone (DDS) in Philippine subjets. Am. J. Trop. Med. Hyg., 21:450-457, 1972.
57. PETERS, J. H.; GORDON, G. R.; KARAT, A. B. A.; MEYERS, W. M. Metabolic disposition of dapsone in Indian and African subjects. In: ANNUAL LEPROSY RESEARCH CONFERENCE, 7th, California, 1972 apud Int. J. Leprosy, 40(2) :221-222, 1972.
58. PETERS, J. H.; GORDON, G. R.; LEVY, L.; STORKAN, M. A.; JACOBSON, R. R.; ENNA, C. D.; KIRCHHEIMER, W. F. Metabolic disposition of dapsone in patients with dapsone-resistant leprosy. Am. J. Trop. Med. Hyg., 23:222-230, 1972.
59. PETTIT, J. H. S. & CHIN, J. Does glucose-6-phosphate dehydrogenase defi- ciency modify the course of leprosy or its treatment. Lepr. Rev., 35(4): 149-156, 1964.
60. POVEY, M. S. & HORTON, R. J. Leprosy and blood groups. Lepr. Rev. 37:147-150, 1966.
61. RAMOS E SILVA, J. Sur le traitement de la 16pre, en particulier de l'hypodermite nodulaire lepromateuse recidivante par la griseofulvine. Dermat. Internat., 7:37-42, 1968 apud /nt. J. Leprosy, 37:208, 1969.
62. BEES, R. J. W. Rifampicin as therapy in lepromatous leprosy. Star, 33 (4): 5, 12, 1974.
63. REES, R. J. W.; PEARSON, J. M. H.; WATERS, M. F. R. Experimental and clinical studies on rifampicin in the treatment of leprosy. Br. Med. J., 1:89-92, 1970.
64. SCHWANTES, A. R.; SALZANO, F. M.; CASTRO, I. V.; TONDO, C. V. Haptoglobins and leprosy. Acta Genet. (Basel), 17:127-136, 1967.
65. SHEPARD, C. C. The first decade in experimental leprosy. Bull. World Health Organ., 44(6) :821-827, 1971.
66. SHESKIN, J. Further observation with thalidomide in lepra reactions. Lepr. Rev., 36:183-187, 1965.
67. SLOAN, N. R.; JANO, B.; WORTH, R. M.; FASAL, P.•' SHEPARD, C. C. Repository acedapsone in leprosy chemoprophylaxis and treatment. Lancet, 2:525-526, 1971.
68. SOUZA-LIMA, L. Considerageies sobre o real valor da sulfonoterapia nos pro- gramas de profilaxia da lepra. Rev. Bras. Leprol., 86(1/4) :31-36, 1968/ 1969.
69. SUNAHARA, S.; URANO, M.; LIN, H. T.; CHEG, T. J.•' JARUMILINDA, A. Further observations on trimodality of frequency distribution curve of bio- logically ative isoniazid blood levels and 'cline' in frequencies of alleles controlling isoniazid inactivation. Acta Tuberc. Pneumol. Scand., 43 :181- 195, 1963.
70. SUNAHARA, S.; URANO, M.; OGAWA, M. Genetical and geographic studies on isoniazid inactivation. Science, 134:1530-1531, 1961.
71. TAUSSIG, H. B. A study of the German outbreak of phocomelia. The tha- lidomide syndrome. J. Amer. med. Ass., /80:1106-1113, 1962.
72. TUBERCULOSIS CHEMOTHERAPY CENTRE, Madras. A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis. Bull. World Health Organ., 48(1): 143-206, 1970.73. VESELL, E. S. Recent progress in pharmacogenetics. Adv. Pharmacol. Chemother., 7:1-52, 1969.
74. WEINSTEIN, L. Medicamentos utilizados na quimioterapia da lepra e da tuberculose. In: GOODMAN, L. S. & GILMAN, A., ed. As bases farmacológicas da terapêutica. [trad. de Lauro SoHero] 4.a ed. Rio de Janeiro, Guanabara Koogan, 1973. cap. 61, p. 1211-1241.
75. WOLF, M. Dermatitis herpetiformis: response to diaminodiphenylsulfone. Arch. Derm,atol., 82(6) :1020-1021, 1960.
76. WORLD HEALTH ORGANIZATION. Technical Report Series. WHO expert committee on leprosy. Fourth report. Geneva, n.° 459, 1970.
77. YOSHIDA, A. Hemolytic anemia and G6PD deficiency. Science, 179 :532- 537, 1973.
78. ZINKHAM, W. H.; LENHARD JR., R. E.; CHILDS, B. Deficiency of glucose 6-phosphate dehydrogenase activity in erythrocytes from patients with favism. Bull. Johns Hopkins Hosp., 102:169-175, 1958.
This journal is licensed under a Creative Commons Attribution 4.0 International License.
Downloads
Download data is not yet available.
